Navigation Links
Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
Date:3/31/2008

SHANGHAI, China, March 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech, the leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, was very honored to have Professor David W. C. MacMillan, a renowned researcher from Princeton University, as a WuXi PharmaTech Science Seminar Series speaker who delivered a lecture to the company's young scientists on March 25, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Aiming to keep the company's young scientists abreast of the latest drug R&D knowledge and technologies, the WuXi PharmaTech Science Seminar Series is a monthly program that invites accomplished researchers from academia and the industry to share their wealth of experience and expertise with the company's scientists.

Dr. David MacMillan obtained his undergraduate degree from Glasgow University, and in 1990 moved to the University of California, Irvine, where he obtained his Ph.D. under the direction of Larry E. Overman. Following postdoctoral research with David A. Evans at Harvard University, Dr. MacMillan began his independent research career at the University of California, Berkeley, in 1998. In 2000, he joined the department of chemistry at Caltech, and was promoted to full professor in 2003. He was appointed to the A. Barton Hepbum Chair of Chemistry and Director of the Merck Center for Catalysis at Princeton University in June 2006.

Dr. MacMillan is a leader in the currently active area of asymmetric organocatalysis. His numerous accomplishments have found widespread industrial application and his success is evidenced by the numerous awards and honors he has received from professional associations like the Royal Society of Chemistry, the American Chemical Society and the industry.

"We are very honored and privileged to have Dr. MacMillan as one of our seminar speakers. His remarkable achievements in the field of organic synthesis will motivate our young scientists," said Dr. Shuhui Chen, Chief Scientific Officer of the company. "As a research-driven company serving global pharmaceutical, biotechnology and medical device companies, we believe science has no boundary. We will continue inviting heavy-weight speakers to WuXi so that our scientists can learn from the best, and ultimately provide better services to our customers."

About WuXi PharmaTech

WuXi PharmaTech, headquartered in Shanghai, China, is a leading global pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the U.S. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology and medical device companies. Our services are designed to assist our global customers in shortening the time and lowering the cost of drug and medical device R&D by providing cost- effective and efficient outsourcing solutions. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Princeton scientists break choleras lines of communication
2. First look: Princeton researchers peek into deepest recesses of human brain
3. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
4. University of Iowa professor identifies new eating disorder
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
7. N.J. nurses are overworked according to Rutgers College of Nursing professor
8. Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award
9. Boston University School of Medicine Professor receives award from American Heart Association
10. Louisiana Tech professor is Small Times Innovator of the Year
11. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... ... 2016 , ... LaserShip, a regional parcel carrier that services the eastern U.S., ... last Friday in order to aid in the Flint water crisis. In 2014, LaserShip ... located in Clio, only 15 miles away from Flint. , “We have deep roots ...
(Date:2/10/2016)... Washington (PRWEB) , ... February 10, 2016 , ... ... access and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart ... remote interpreting (VRI). , For nearly 23 years, Heart City Health Center has ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... United ... Nesbitt as the latest addition to its growing list of Partner Firms. ... the Southeast, from Orlando to Huntsville and in between. , Harnessing the experience ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 --> ... Gas), and Spectroscopy Market by Industry (Oil & Gas, Petrochemical, ... Paper, Metal & Mining, and Others), And Geography - ... market is expected to grow to USD 3.9 Billion ... 2015 and 2020. Browse 82 market data ...
(Date:2/10/2016)... -- Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company ... of lupus and Sjogrens syndrome, today announced the ... in patients with systemic lupus erythematosus (SLE) with ... --> Data from a multicenter ... RSLV-132 in 32 subjects with SLE demonstrate the ...
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
Breaking Medicine Technology: